FloDesign Sonics develops acoustic technologies for the separation, concentration and purification of materials in an active fluid. The company's key focus is cell therapy, particularly processing and purification steps for CAR T cells. Its platform aims to address manufacturing challenges related to processing, separation and purification in cell therapy production. Founded in 2010 by Stanley Kowalski, the company is based in Wilbraham, Massachusetts. Financially, the company has recently closed a Series A2 financing of undisclosed size. FloDesign Sonics intends to use the proceeds to advance the commercial production of CAR T and other immunotherapies. FloDesign Sonics develops an acoustic separation technology platform that uses 3D acoustic standing waves to capture, separate and purify without physical membranes, chemicals or centrifugation. The company intends to apply this proprietary technology across multiple markets, including life sciences, oil and gas, food and beverage and industrial processing. Its first commercial application targets bioprocess separations for the manufacturing of biopharmaceuticals. FloDesign Sonics closed a $10M Series A to advance development and commercialization of the platform in the bioprocessing market. The company plans to use the funds to further develop the core technology and fund commercialization efforts. Leadership includes founder and CTO Dr. Bart Lipkens, CEO Stanley Kowalski III, and co-founder and Executive Vice President Louis Masi.

Total raised

$10M

Funding rounds

2

Latest round

Series A

Latest activity

Apr 2014